How long does it take for the targeted drug Pralsetinib to start taking effect?

Pralsetinib is an oral targeted drug mainly used to treat non-small cell lung cancer (NSCLC) and certain types of thyroid cancer carrying RET gene fusion. The drug works relatively quickly in a group of patients with precise targets. Generally, some patients can experience initial therapeutic effects such as tumor shrinkage, symptom relief or tumor marker level decline within 2 to 4 weeks after taking the drug. However, the specific onset time of each patient will be affected by factors such as individual constitution, tumor burden, and disease progression.

Clinical study data show that among patients treated with platinib, most patients observed tumor shrinkage on imaging within the first course of treatment (about 4 weeks), especially for RETFusion-positive lung cancer patients have a higher objective response rate (ORR), which means that platinib can exert a significant anti-tumor effect in the short term. Patients with obvious symptoms, such as dyspnea and cough, can often be relieved in the early stages of treatment.

However, it should be noted that not all patients can achieve obvious results in a short period of time. For patients with larger tumors, longer disease duration, or other health problems, the onset of action may be delayed. Doctors usually recommend taking the medication for at least 8 weeks before evaluating the efficacy. If the efficacy is significant and well tolerated, long-term medication can be continued to maintain control. In the process of efficacy evaluation, comprehensive judgment needs to be made by combining imaging examinations (such as CT or MRI) and tumor marker detection.

In short, platinib is a precise targeted drug that works quickly, but patients should take the medication regularly and have regular reviews during treatment. It is necessary to cooperate with genetic testing before and after treatment to ensure that there is a RET fusion mutation before you can benefit. At the same time, it is necessary to communicate closely with the attending doctor to monitor whether side effects occur, and adjust the dosage or treatment plan according to the efficacy in order to obtain more lasting clinical benefits.

Reference materials:https://gavreto.com/